abrocitinib AD
Selected indexed studies
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (N Engl J Med, 2021) [PMID:33761207]
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (Lancet, 2020) [PMID:32711801]
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (JAMA Dermatol, 2020) [PMID:32492087]
_Worker-drafted node — pending editorial review._
Connections
abrocitinib AD is a side effect of
Sources
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (2021) pubmed
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2020) pubmed
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2020) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis. (2025) pubmed
- JAK inhibitors in the treatment of atopic dermatitis. (2021) pubmed
- JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. (2022) pubmed
- Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. (2024) pubmed
- Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis. (2024) pubmed
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. (2024) pubmed